SCHEMBL2565597

SCHEMBL2565597

[C]#CC1CCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572277 0.82
SCHEMBL26494 0.75
SCHEMBL419893 0.69
SCHEMBL16032348 0.69
SCHEMBL56272 0.69
SCHEMBL95760 0.69
Hydrochloric Acid SCHEMBL28290254 0.67
SCHEMBL17761626 0.65
SCHEMBL7362288 0.62
SCHEMBL10704607 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556191-B2 Aminoquinazoline derivatives and their salts and methods of use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-01-31 US disclosed
US-20160039838-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-02-11 US disclosed
WO-2014177038-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-11-06 WO disclosed
EP-2382972-A1 Methods for preventing and treating neurodegenerative disorders Boehringer Ingelheim International GmbH (DE) 2011-11-02 EP disclosed
US-20100081625-A1 METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 US disclosed